Bendamustine (Levact®) Plus Rituximab More Effective Than CHOP-R In Treating Patients With Indolent Non-Hodgkin Lymphoma And Mantle Cell LymphomaMain Category: Lymphoma / Leukemia / Myeloma
Article Date: 22 Feb 2013
Treatment with bendamustine plus rituximab (B-R) doubles progression free survival (PFS) compared with current standard of care CHOP-R (69.5 versus 31.2 months; p<0.0001)
Results from the StiL NHL-1 study published in The Lancet this week show that a first-line treatment regimen of bendamustine plus rituximab (B-R) doubles progression-free survival (PFS) compared with the most often used treatment CHOP plus rituximab (CHOP-R), in newly diagnosed patients with indolent non-Hodgkin lymphoma (iNHL) and mantle cell lymphoma (MCL).1
Median PFS for patients treated with B-R was 69.5 months, compared with 31.2 months for patients treated with CHOP-R, the most common chemoimmunotherapy regimen used for the treatment of these diseases (p<0.0001).1
The statistically significant PFS benefit was maintained in the B-R group, regardless of age and across all subtypes; follicular lymphoma, MCL and Waldenström's macroglobulinaemia, with the exception of marginal zone lymphoma, which was non-inferior.1
The results also represent the first time that a simplified treatment regimen has led to a superior complete response (CR) rate compared to CHOP-R in a randomised trial, with 40% of the B-R group achieving a CR compared with 30% for CHOP-R (p=0.021).1 The B-R group also experienced fewer side effects to those receiving CHOP-R, with serious adverse events occurring in 19% of the B-R group compared with 29% for patients receiving CHOP-R.1
Patients receiving B-R experienced less myelosuppression, with severe neutropenia occurring in only 29% of patients compared to 69% with CHOP-R (p<0.0001).1 Infections, a challenging side effect of chemoimmunotherapy, were also significantly reduced with the B-R regimen (p=0.0025).1 A commonly acknowledged side effect of CHOP-R is hair loss; however, hair loss was not reported in a single patient receiving B-R (p<0.0001).1
"These results represent a significant breakthrough in cancer treatment for patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma, who in the past have had to endure particularly aggressive and toxic chemotherapy combinations," said Professor Mathias J. Rummel, Head of the Department for Haematology at the University Hospital in Giessen, Germany, who led the study. "Our study showed bendamustine and rituximab offered a significant improvement in PFS, and that the combination was better tolerated than CHOP-R. This means that the regimen, if approved by the regulatory authorities, could become the new preferred first-line treatment, capable of extending the time patients battling these malignancies live free of disease."
"The results of this study are very encouraging for indolent non-Hodgkin lymphoma patients," said Professor John Gribben, Chair of the International Workshop on non-Hodgkin Lymphoma. "The fact that bendamustine and rituximab results in fewer adverse effects with significantly better efficacy than the traditional CHOP-R treatment regimen indicates that this could be a new cornerstone in the treatment of NHL."
Non-Hodgkin lymphoma (NHL) is the tenth most common cancer worldwide and figures from 2008 indicate that there are an estimated 356,000 new cases diagnosed every year, comprising two out of five haematological cancers.2 Indolent lymphomas represent 40% and MCL 3-10% of all NHL subtypes.1 The estimated average incidence of NHL in 2008 in the European Union is 10.8 per 100,000, with the highest estimated incidence being for men living in Luxembourg (around 19 cases per 100,000).2, 3
Bendamustine is currently licensed as a monotherapy for the treatment of iNHL in patients who have progressed during, or within 6 months following, treatment with rituximab or a rituximab containing regimen. Data from the StiL NHL-1 study have been submitted to regulatory authorities for their consideration of a bendamustine and rituximab combination as a first-line treatment for iNHL and MCL.
StiL NHL-1 Study Methodology
The StiL NHL-1 study was a prospective, open-label, multi-centre, randomised phase 3 non-inferiority trial, which involved 549 patients aged 18 years or older, with newly diagnosed stage III or IV indolent NHL and MCL.1 Patients were stratified according to histological lymphoma subtype and then randomised to receive bendamustine 90mg/m2 on days 1 and 2 of a 4-week cycle or CHOP (3-weekly cycles of cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2 and vincristine 1.4 mg/m2 on day 1, and prednisone 100 mg/day for 5 days) for a maximum of 6 cycles. Patients in both treatment arms received rituximab 375 mg/m2 on day 1 of each cycle.1
CHOP-R Treatment Regimen
Rituximab plus chemotherapy, most commonly CHOP-R, is the current first-line standard of care for patients with advanced iNHL, and for elderly patients with MCL.1
Original article posted on Medical News Today.
Articles not to be reproduced without permission of Medical News Today